US 12,116,423 B2
Ang (1-7) derivative oligopeptides and methods for using and producing the same
Meredith Hay, Tucson, AZ (US); John Konhilas, Tucson, AZ (US); Robin L. Polt, Tucson, AZ (US); Evan Jones, Tucson, AZ (US); and Lajos Szabo, Tucson, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, Tucson, AZ (US)
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, Tucson, AZ (US)
Filed on Aug. 30, 2021, as Appl. No. 17/461,115.
Application 17/461,115 is a continuation of application No. 16/751,120, filed on Jan. 23, 2020, granted, now 11,104,706.
Application 16/751,120 is a continuation of application No. 15/691,586, filed on Aug. 30, 2017, granted, now 10,550,156, issued on Feb. 4, 2020.
Application 15/691,586 is a continuation of application No. 14/801,557, filed on Jul. 16, 2015, granted, now 9,796,759, issued on Oct. 24, 2017.
Claims priority of provisional application 62/027,219, filed on Jul. 21, 2014.
Prior Publication US 2021/0395308 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/14 (2006.01); A61K 38/00 (2006.01); A61K 38/04 (2006.01); A61K 38/08 (2019.01); C07K 7/06 (2006.01); C07K 9/00 (2006.01)
CPC C07K 7/14 (2013.01) [A61K 38/04 (2013.01); A61K 38/085 (2013.01); C07K 7/06 (2013.01); C07K 9/001 (2013.01); A61K 38/00 (2013.01)] 16 Claims
 
1. A method for treating conditions associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species that can cause cognitive dysfunction and/or impairment in a subject comprising systemically administering to the subject a therapeutically effective amount of a heptapeptide having the formula: A1-A2-A3-A4-A5-A6-A7-A8 (SEQ ID NO:1) wherein A1 is selected from the group consisting of aspartic acid, glutamic acid, alanine, and glycosylated forms thereof; A2 is selected from the group consisting of arginine, histidine, lysine, and glycosylated forms thereof; A3 is selected from the group consisting of valine, alanine, isoleucine, leucine, and glycosylated forms thereof; A4 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and glycosylated forms thereof; A5 is selected from the group consisting of isoleucine, valine, alanine, leucine, and glycosylated forms thereof; A6 is selected from the group consisting of histidine, arginine, lysine, and glycosylated forms thereof; A7 is serine or a glycosylated form thereof; and A8 is absent.